Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer.

Genes & development - 2 Feb 2026

Shao Chunlei, Indeglia Alexandra, Foster Maya, Casey Kaitlyn, Leung Jessica, Modarai Shirin R, Leu Julia I-Ju, Duong Bryant, Mes-Masson Anne-Marie, Sims-Mourtada Jennifer, Auslander Noam, Drapkin Ronny, Bitler Benjamin G, Zhang Nan, Murphy Maureen E

Abstract excerpt

High-grade serous ovarian cancer (HGSOC) is a highly lethal gynecologic malignancy in women. Women diagnosed with HGSOC initially respond to chemotherapy, but there is a >80% rate of relapse. There is thus a significant unmet need for new therapeutic targets for HGSOC. Estrogen receptor α (ERα) is a particularly attractive candidate, as ∼70% of HGSOC tumors stain positively for ERα and there are approved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estradiol

Share to Estrogen Receptor alpha

Share to Fulvestrant

Share to Mutation, Missense

Share to Ovarian Neoplasms

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 41193244
DOI: 10.1101/gad.352953.125
PMCID: PMC12829591

Genes

SP1
DEPTOR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer.PMID 41193244Read ↗

Recent Advances of Wee1 Inhibitors and Statins in Gynecologic Cancers with p53 MutationsSemantic proximity Read ↗

Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast CancerSemantic proximity Read ↗

Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and are Killed by BHPI.Semantic proximity Read ↗

ERβ alters the chemosensitivity of luminal breast cancer cells by regulating p53 functionSemantic proximity Read ↗

p53, a Target of Estrogen Receptor (ER) α, Modulates DNA Damage-induced Growth Suppression in ER-positive Breast Cancer CellsSemantic proximity Read ↗

Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.Semantic proximity Read ↗

Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.Semantic proximity Read ↗

The natural L370F ERα Variant Confers Endocrine Resistance and Sensitivity to ATRA in Metastatic Breast Cancer CellsSemantic proximity Read ↗

The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer.Semantic proximity Read ↗

The natural L370F ERα variant confers endocrine resistance and sensitivity to ATRA in metastatic breast cancer cells.Semantic proximity Read ↗

Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer.Semantic proximity Read ↗

Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid HormonesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.